

Joe Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5561462/publications.pdf>

Version: 2024-02-01

29
papers

1,943
citations

471509

17
h-index

580821

25
g-index

29
all docs

29
docs citations

29
times ranked

2896
citing authors

#	ARTICLE	IF	CITATIONS
1	Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. <i>Cell Stem Cell</i> , 2013, 12, 101-113.	11.1	584
2	Fast two-photon imaging of subcellular voltage dynamics in neuronal tissue with genetically encoded indicators. <i>ELife</i> , 2017, 6, .	6.0	161
3	Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy. <i>Nature</i> , 2019, 572, 335-340.	27.8	136
4	Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer. <i>Circulation</i> , 2019, 139, 2451-2465.	1.6	136
5	Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells. <i>Circulation</i> , 2018, 138, 2666-2681.	1.6	112
6	Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. <i>Nature Protocols</i> , 2018, 13, 3018-3041.	12.0	102
7	A Human iPSC Double-Reporter System Enables Purification of Cardiac Lineage Subpopulations with Distinct Function and Drug Response Profiles. <i>Cell Stem Cell</i> , 2019, 24, 802-811.e5.	11.1	102
8	Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients. <i>European Heart Journal</i> , 2019, 40, 3685-3695.	2.2	100
9	A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. <i>Circulation</i> , 2019, 139, 799-811.	1.6	91
10	Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E11111-E11120.	7.1	68
11	Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	56
12	Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction. <i>Stem Cell Reports</i> , 2018, 10, 422-435.	4.8	49
13	Single-Cell RNA Sequencing of Human Embryonic Stem Cell Differentiation Delineates Adverse Effects of Nicotine on Embryonic Development. <i>Stem Cell Reports</i> , 2019, 12, 772-786.	4.8	47
14	Progress in multicellular human cardiac organoids for clinical applications. <i>Cell Stem Cell</i> , 2022, 29, 503-514.	11.1	39
15	Cellular and Engineered Organoids for Cardiovascular Models. <i>Circulation Research</i> , 2022, 130, 1780-1802.	4.5	27
16	Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes. <i>STAR Protocols</i> , 2021, 2, 100334.	1.2	24
17	DUSP26 induces aortic valve calcification by antagonizing MDM2-mediated ubiquitination of DPP4 in human valvular interstitial cells. <i>European Heart Journal</i> , 2021, 42, 2935-2951.	2.2	24
18	Disruption of mesoderm formation during cardiac differentiation due to developmental exposure to 13-cis-retinoic acid. <i>Scientific Reports</i> , 2018, 8, 12960.	3.3	19

#	ARTICLE	IF	CITATIONS
19	RNA Sequencing Analysis of Induced Pluripotent Stem Cell-Derived Cardiomyocytes From Congenital Heart Disease Patients. <i>Circulation Research</i> , 2020, 126, 923-925.	4.5	17
20	Interoperability in NHS hospitals must be improved: the Care Quality Commission should be a key actor in this process. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 101-104.	2.0	12
21	Protocol to measure contraction, calcium, and action potential in human-induced pluripotent stem cell-derived cardiomyocytes. <i>STAR Protocols</i> , 2021, 2, 100859.	1.2	12
22	Effects of Cryopreservation on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Assessing Drug Safety Response Profiles. <i>Stem Cell Reports</i> , 2021, 16, 168-181.	4.8	10
23	Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies. <i>JCI Insight</i> , 2021, 6, .	5.0	8
24	Applications of genetically engineered human pluripotent stem cell reporters in cardiac stem cell biology. <i>Current Opinion in Biotechnology</i> , 2018, 52, 66-73.	6.6	6
25	Abstract 243: Modeling of Diastolic Dysfunction in Induced Pluripotent Stem Cell-derived Cardiomyocytes From Hypertrophic Cardiomyopathy Patients. <i>Circulation Research</i> , 2018, 123, .	4.5	1
26	Abstract 442: Modeling Endothelial Dysfunction in LMNA-Related Dilated Cardiomyopathy. <i>Circulation Research</i> , 2017, 121, .	4.5	0
27	Abstract 6: Restoration of Impaired Diastolic Function in Hypertrophic Cardiomyopathy Induced Pluripotent Stem Cell-derived Cardiomyocytes by Re-balancing the Calcium Homeostasis. <i>Circulation Research</i> , 2017, 121, .	4.5	0
28	Abstract 209: Downregulation of KLF2 in the Endothelium Contributes to the Pathogenesis in LMNA-related Dilated Cardiomyopathy. <i>Circulation Research</i> , 2018, 123, .	4.5	0
29	Abstract 782: Human-induced Pluripotent Stem Cell-derived Cardiomyocytes as a Model for Trastuzumab-Induced Cardiac Dysfunction. <i>Circulation Research</i> , 2019, 125, .	4.5	0